Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336907 | 0.84 | KDM4E (0.42) | NOTUMKDM4EGAALMNAPOLB | |
| SCHEMBL3337607 | 0.80 | MYC (0.36) | NOTUMKDM4EGAALMNAPOLB | |
| SCHEMBL3336263 | 0.80 | NOTUM (0.39) | NOTUMKDM4EGAALMNAPOLB | |
| SCHEMBL23900591 | 0.79 | NOTUM (0.42) | NOTUMKEAP1NFE2L2KDM4EGAA | |
| SCHEMBL2012525 | 0.73 | POLB (0.44) | NOTUMPOLB | |
| SCHEMBL8290253 | 0.70 | HAAO (0.46) | NOTUMKDM4ELMNAPOLBRECQL | |
| SCHEMBL23147363 | 0.70 | NOTUM (0.61) | NOTUMKDM4ELMNAPOLBALDH1A1 | |
| SCHEMBL2010294 | 0.68 | POLB (0.46) | NOTUMKDM4EGAAPOLBALDH1A1 | |
| SCHEMBL961272 | 0.68 | HTR4 (0.57) | POLB | |
| SCHEMBL30827426 | 0.68 | HTR4 (0.57) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | disclosed |
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | KATO TOMOKI | 2010-06-10 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1713797-B1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1713797-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144789-A1 | 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | NOTUM 2684/4885KEAP1 3805/4885NFE2L2 1860/4885 |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | NOTUM 2684/4885KEAP1 3805/4885NFE2L2 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.